Sofosbuvir
Liver Disorder
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Texas Southwestern Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02717949CT.gov Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sofosbuvir (this asset) | University of Texas Southwestern Medical Center | Approved | BB · 65 |
| Pioglitazone | Yonsei University | P4 | BBB |
| Metformin | Taipei City Hospital | P4 | BBB |
| Empagliflozin | Military University Hospital, Prague | P4 | BB |
| 10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one | Tanta University | P4 | BB |
| Glibenclamide | Takeda | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Alpha Tocopherol | Tanta University | P4 | BB |
| Shen Pu Yang Gan Wan | Taipei Medical University WanFang Hospital | P4 | BB |
+42 more in the Liver Disorder cohort
Other indications for Sofosbuvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P4 | A · 82 |
| Chronic Hepatitis C Virus Infection | — | P4 | A · 81 |
| Cirrhosis Of Liver | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sofosbuvir in Liver Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sofosbuvir-liver-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →